Skip to main content

Young Caroline's Form 4 filing

Cumberland Pharmaceuticals Inc (CPIX) · filed May 6, 2022

Accession no.
0001209191-22-027651
Filed
May 6, 2022
Trade date
Apr 14-29, 2022
Filing delay
22 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 11 non-derivative transactions. Open-market purchases total $558.95. It was filed 22 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Young CarolineCIK 0001684087Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 14, 2022Common StockPPurchaseAcquired+19$2.71+$51.4915,796Direct
Apr 18, 2022Common StockPPurchaseAcquired+19$2.63+$49.9715,815Direct
Apr 19, 2022Common StockPPurchaseAcquired+19$2.69+$51.1115,834Direct
Apr 20, 2022Common StockPPurchaseAcquired+19$2.74+$52.0615,853Direct
Apr 21, 2022Common StockPPurchaseAcquired+19$2.75+$52.2515,872Direct
Apr 22, 2022Common StockPPurchaseAcquired+19$2.73+$51.8715,891Direct
Apr 25, 2022Common StockPPurchaseAcquired+20$2.62+$52.415,911Direct
Apr 26, 2022Common StockPPurchaseAcquired+20$2.53+$50.615,931Direct
Apr 27, 2022Common StockPPurchaseAcquired+20$2.41+$48.215,951Direct
Apr 28, 2022Common StockPPurchaseAcquired+20$2.51+$50.215,971Direct
Apr 29, 2022Common StockPPurchaseAcquired+20$2.44+$48.815,991Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)